Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

25 evidence topics · 35 sources

Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor

The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).

Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.

Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy

Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).